CERS — Cerus Corporation stock price, charts and financials

Latest market price

2.19

+0.04+1.86%

Overview Short InterestFilings

CERSQT57Cerus Corporation·NASDAQ

Overview Short InterestFilings

2.19+1.86%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PACB+1.41%$1.44 DCTH+0.77%$13.14 NPCE+4.74%$14.14 OFIX-0.49%$12.20 CLPT-16.25%$12.88 VREX+3.78%$12.37 KIDS+0.05%$20.88 CTKB-0.70%$4.28

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.10	Insider Own	8.41%	Shs Outstand	200.37M	Perf Week	-25.00%

Market Cap	438.81M	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-9.07%	Shs Float	189.49M	Perf Month	-33.23%

Enterprise Value	424.81M	PEG	-	EPS next Q	-0.01	Inst Own	-	Short Float	7.22%	Perf Quarter	-19.49%

Income	-20.00M	P/S	2.29	EPS this Y	60.00%	Inst Trans	-	Short Ratio	5.08	Perf Half Y	-5.60%

Sales	192.00M	P/B	6.18	EPS next Y	66.67%	ROA	-3.31%	Short Interest	13.69M	Perf YTD	6.31%

Book/sh	0.35	P/C	7.84	EPS next 5Y	-	ROE	-10.28%	52W High	3.47 -36.89%	Perf Year	72.44%

Cash/sh	0.28	P/FCF	-	EPS past 3/5Y	-	ROIC	-5.53%	52W Low	1.15 90.43%	Perf 3Y	-25.76%

Dividend Est.	-	EV/EBITDA	183.60	Sales past 3/5Y	8.34% 17.49%	Gross Margin	53.36%	Volatility	7.42% 5.79%	Perf 5Y	-54.37%

Dividend TTM	-	EV/Sales	2.21	EPS Y/Y TTM	9.09%	Oper. Margin	-3.71%	ATR (14)	0.21	Perf 10Y	-67.07%

Dividend Ex-Date	-	Quick Ratio	1.07	Sales Y/Y TTM	6.67%	Profit Margin	-2.98%	RSI (14)	28.35	Recom	2.20

Dividend Gr. 3/5Y	-	Current Ratio	1.83	EPS Q/Q	-	SMA20	-25.03%	Beta	1.73	Target Price	4.00

Payout	0.00%	Debt/Eq	1.45	Sales Q/Q	9.62%	SMA50	-22.71%	Rel Volume	2.33	Prev Close	2.15

Employees	275	LT Debt/Eq	0.78	Earnings	Nov 05	SMA200	-2.19%	Avg Volume	2.68M	Price	2.19

IPO Date	Jan 31, 1997	Option/Short	No / Yes	EPS/Sales Surpr.	25.00% 0.64%	Net Debt/EBITDA	9.69	Volume	6,251,448	Change	1.86%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-01-26	Upgrade	BTIG	Neutral → Buy	$4.00
Oct-17-24	Reiterated	Stifel Nicolaus		$3.00
May-03-24	Reiterated	Cantor Fitzgerald	Overweight	$4.00
Apr-12-24	Reiterated	Craig-Hallum		$5.00
Jan-20-23	Downgrade	BTIG	Buy → Neutral
Nov-13-19	Upgrade	BTIG	Neutral → Buy
Dec-17-15	Downgrade	Wedbush	Outperform → Neutral

Latest News

Jul-30-26

Jul-30-2611:33PM

Cerus Corporation (CERS) Q2 2026 Earnings Call Transcriptseekingalpha.com

08:43PM

Cerus Corp (NASDAQ:CERS) Drops 10% After Q2 Revenue Beat Overshadowed by Lowered Full-Year GuidanceChartMill

06:06PM

Cerus Q2 Earnings Call Highlightsmarketbeat.com

04:01PM

Cerus Corporation Announces Second Quarter 2026 Financial Resultsbusinesswire.com

Jul-21-26

Jul-21-2603:17AM

Amova Asset Management Americas Inc. Sells 193,353 Shares of Cerus Corporation $CERSdefenseworld.net

Jul-16-26

Jul-16-2604:01PM

Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026businesswire.com

Jul-10-26

Jul-10-2604:40PM

Cerus Announces William Greenman Ceases As President And CEO, Becomes Executive Chairman Effective July 1, 2026Benzinga

Company

Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	192	206	180	156	162	131	92	75	61
Cost of Goods Sold Incl. D&A	84	96	81	70	75	63	41	33	32
Gross Profit	107	110	100	86	87	67	51	41	29
Selling, General and Administrative Excl. Other	78	81	76	76	83	81	67	66	57
Research and Development	65	66	59	68	64	64	64	60	43
Other Operating Expense	-10	0	-21	-28	-26	-29	-22	-19	-16
Operating Income	-24	-36	-14	-30	-34	-49	-58	-66	-55
Interest Expense	8	8	9	8	6	5	4	6	4
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	15	29	2	1	-2	0	3	1	2
Net Income Before Taxes	-19	-15	-21	-37	-42	-54	-60	-71	-57
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-20	-16	-21	-37	-43	-54	-60	-71	-58
Net Income From Continuing Operations	-20	-16	-21	-38	-43	-54	-60	-71	-58
Net Income	-20	-16	-21	-37	-43	-54	-60	-71	-58
EPS (Recurring)	-0.10	-0.08	-0.11	-0.21	-0.24	-0.32	-0.37	-0.51	-0.44
EPS (Basic, Before Extraordinaries)	-0.10	-0.08	-0.11	-0.21	-0.24	-0.32	-0.37	-0.51	-0.44
EPS (Diluted)	-0.10	-0.08	-0.11	-0.21	-0.24	-0.32	-0.37	-0.51	-0.44
EBITDA	-8	-5	-10	-26	-34	-46	-51	-65	-52
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	2.18	1.91	1.58	2.49	3.99	8.89	12.34	7.88	10.89
Gross Margin	55.73	53.40	55.56	55.13	53.70	51.15	55.43	54.67	47.54
Operating Margin	-12.50	-17.48	-7.78	-19.23	-20.99	-37.40	-63.04	-88.00	-90.16
Net Margin	-10.42	-7.77	-11.67	-23.72	-26.54	-41.22	-65.22	-94.67	-95.08
Shares Outstanding	191	191	185	180	177	171	164	140	131
Market Capitalization	418	393	285	389	646	1,165	1,135	591	664
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jayaraman Vivek K	Chief Executive Officer	Jul 16 '26	Sale	3.16	16,666	52,665	2,232,211	Jul 20
Jayaraman Vivek K	Chief Operating Officer	Jun 30 '26	Sale	2.94	42,359	124,658	1,694,348	Jul 02
Jensen Chrystal	Chief Legal Officer	Jun 30 '26	Sale	2.94	24,329	71,598	966,657	Jul 02
Greenman William Mariner	President and CEO	Jun 30 '26	Sale	2.94	101,919	299,937	5,053,036	Jul 02
Green Kevin Dennis	Chief Financial Officer	Jun 30 '26	Sale	2.94	33,676	99,105	1,062,188	Jul 02
BJERKHOLT ERIC	Director	Jun 09 '26	Sale	2.60	20,454	53,180	261,679	Jun 11
Jayaraman Vivek K	Chief Operating Officer	May 29 '26	Sale	3.00	16,667	50,001	1,656,707	Jun 02
Jayaraman Vivek K	Chief Operating Officer	May 01 '26	Sale	3.00	16,667	50,001	1,673,374	May 05
Greenman William Mariner	President and CEO	Mar 12 '26	Sale	1.66	447,757	742,023	4,998,493	Mar 16
Jayaraman Vivek K	Chief Operating Officer	Mar 12 '26	Sale	1.66	165,200	273,769	1,747,674	Mar 16
Green Kevin Dennis	Chief Financial Officer	Mar 12 '26	Sale	1.66	127,544	211,366	1,040,551	Mar 16
Benjamin Richard J	Chief Medical Officer	Mar 12 '26	Sale	1.66	101,740	168,604	777,361	Mar 16
Jensen Chrystal	Chief Legal Officer	Mar 12 '25	Sale	1.66	113,008	187,277	946,131	Mar 16
Benjamin Richard J	Chief Medical Officer	Mar 05 '26	Sale	2.06	122,466	252,604	943,762	Mar 10
Benjamin Richard J	Chief Medical Officer	Mar 09 '26	Sale	1.88	40,426	76,029	879,101	Mar 09

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.